Dataset Information

Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer.

ABSTRACT: Background:The first generation CDK2/7/9 inhibitor seliciclib (CYC202) causes multipolar anaphase and apoptosis in lung cancer cells with supernumerary centrosomes (known as anaphase catastrophe). We investigated a new and potent CDK2/9 inhibitor, CCT68127 (Cyclacel). Methods:CCT68127 was studied in lung cancer cells (three murine and five human) and control murine pulmonary epithelial and human immortalized bronchial epithelial cells. Robotic CCT68127 cell-based proliferation screens were used. Cells undergoing multipolar anaphase and inhibited centrosome clustering were scored. Reverse phase protein arrays (RPPAs) assessed CCT68127 effects on signaling pathways. The function of PEA15, a growth regulator highlighted by RPPAs, was analyzed. Syngeneic murine lung cancer xenografts (n?=?4/group) determined CCT68127 effects on tumorigenicity and circulating tumor cell levels. All statistical tests were two-sided. Results:CCT68127 inhibited growth up to 88.5% (SD?=?6.4%, P < .003) at 1??M, induced apoptosis up to 42.6% (SD?=?5.5%, P < .001) at 2??M, and caused G1 or G2/M arrest in lung cancer cells with minimal effects on control cells (growth inhibition at 1??M: 10.6%, SD?=?3.6%, P = .32; apoptosis at 2??M: 8.2%, SD?=?1.0%, P = .22). A robotic screen found that lung cancer cells with KRAS mutation were particularly sensitive to CCT68127 ( P = .02 for IC 50 ). CCT68127 inhibited supernumerary centrosome clustering and caused anaphase catastrophe by 14.1% (SD?=?3.6%, P < .009 at 1??M). CCT68127 reduced PEA15 phosphorylation by 70% (SD?=?3.0%, P = .003). The gain of PEA15 expression antagonized and its loss enhanced CCT68127-mediated growth inhibition. CCT68127 reduced lung cancer growth in vivo ( P < .001) and circulating tumor cells ( P = .004). Findings were confirmed with another CDK2/9 inhibitor, CYC065. Conclusions:Next-generation CDK2/9 inhibition elicits marked antineoplastic effects in lung cancer via anaphase catastrophe and reduced PEA15 phosphorylation.

SUBMITTER: Kawakami M

PROVIDER: S-EPMC6059250 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer.

Kawakami Masanori M Mustachio Lisa Maria LM Rodriguez-Canales Jaime J Mino Barbara B Roszik Jason J Tong Pan P Wang Jing J Lee J Jack JJ Myung Ja Hye JH Heymach John V JV Johnson Faye M FM Hong Seungpyo S Zheng Lin L Hu Shanhu S Villalobos Pamela Andrea PA Behrens Carmen C Wistuba Ignacio I Freemantle Sarah S Liu Xi X Dmitrovsky Ethan E

Journal of the National Cancer Institute 20170601 6

<h4>Background</h4>The first generation CDK2/7/9 inhibitor seliciclib (CYC202) causes multipolar anaphase and apoptosis in lung cancer cells with supernumerary centrosomes (known as anaphase catastrophe). We investigated a new and potent CDK2/9 inhibitor, CCT68127 (Cyclacel).<h4>Methods</h4>CCT68127 was studied in lung cancer cells (three murine and five human) and control murine pulmonary epithelial and human immortalized bronchial epithelial cells. Robotic CCT68127 cell-based proliferation scr ...[more]

PMID: 28376145

Similar Datasets

Project description:Tyrosine kinase inhibitors (TKIs) against the human epidermal growth factor receptor (EGFR) are now standard treatment in the clinic for patients with advanced EGFR mutant non-small-cell lung cancer (NSCLC). First-generation EGFR TKIs, binding competitively and reversibly to the ATP-binding site of the EGFR tyrosine kinase domain, have resulted in a significant improvement in outcome for NSCLC patients with activating EGFR mutations (L858R and Del19). However, after a median duration of response of ~12?months, all patients develop tumor resistance, and in over half of these patients this is due to the emergence of the EGFR T790M resistance mutation. The second-generation EGFR/HER TKIs were developed to treat resistant disease, targeting not only T790M but EGFR-activating mutations and wild-type EGFR. Although they exhibited promising anti-T790M activity in the laboratory, their clinical activity among T790M+ NSCLC was poor mainly because of dose-limiting toxicity due to simultaneous inhibition of wild-type EGFR. The third-generation EGFR TKIs selectively and irreversibly target EGFR T790M and activating EGFR mutations, showing promising efficacy in NSCLC resistant to the first- and second-generation EGFR TKIs. They also appear to have lower incidences of toxicity due to the limited inhibitory effect on wild-type EGFR. Currently, the first-generation gefitinib and erlotinib and second-generation afatinib have been approved for first-line treatment of metastatic NSCLC with activating EGFR mutations. Among the third-generation EGFR TKIs, osimertinib is today the only drug approved by the Food and Drug Administration and the European Medicines Agency to treat metastatic EGFR T790M NSCLC patients who have progressed on or after EGFR TKI therapy. In this review, we summarize the available post-progression therapies including third-generation EGFR inhibitors and combination treatment strategies for treating patients with NSCLC harboring EGFR mutations and address the known mechanisms of resistance.

Dataset Information

Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer.

Publications

Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets